Beeline Medicines Launches with $300M Series A to Build Precision Autoimmune Pipeline

Stamford, CT and Boston, MA, April 15, 2026 (Globe Newswire) -- Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, debuting with a portfolio of five clinical and preclinical programs in-licensed from Bristol Myers Squibb. The company's lead asset, afimetoran, is a once-daily oral TLR7/8 inhibitor for systemic lupus erythematosus currently in Phase 2, with data expected in the second half of 2026 ahead of a planned pivotal program.

Read full article here.